title: Evaluation of a DNA vaccine candidate co-expressing GP3 and GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) with interferon α/γ in immediate and long-lasting protection against HP-PRRSV challenge.
abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) has become one of the most economically important diseases to the global pork industry. Current vaccination strategies only provide a limited protective efficacy. In this study, a DNA vaccine, pVAX1(©)-α-γ-GP35, co-expressing GP3 and GP5 of PRRSV with interferon α/γ was constructed, and its immediate and long-lasting protection against highly pathogenic PRRSV (HP-PRRSV) challenge were examined in pigs. For immediate protection, the results showed that pVAX1(©)-α-γ-GP35 could provide partially protective efficacy, which was similar to the pVAX1(©)-α-γ (expressing interferon α/γ). For long-lasting protection, pigs inoculated with pVAX1(©)-α-γ-GP35 developed significantly higher PRRSV-specific antibody response, T cell proliferation, IFN-γ, and IL-4, than those vaccinated with pVAX1(©)-GP35 (expressing GP3 and GP5 of PRRSV). Following homologous challenge with HP-PRRSV strain SD-JN, pigs inoculated with pVAX1(©)-α-γ-GP35 showed almost no clinical signs, no lung lesions, and significantly lower viremia, as compared to those in pVAX1(©)-GP35 group. It indicated that pVAX1(©)-α-γ-GP35 could induce enhanced immune responses and provide both immediate and long-lasting protection against HP-PRRSV challenge in pigs. The DNA vaccine pVAX1(©)-α-γ-GP35 might be an attractive candidate vaccine for the prevention and control of HP-PRRSV infections.
authors: Shandong Key Laboratory of Animal Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Sciences, Sangyuan Road No.10, Jinan, China.
authors: Yijun
authors: Y
authors: Du
authors: Jing
authors: J
authors: Qi
authors: Yu
authors: Y
authors: Lu
authors: Jiaqiang
authors: J
authors: Wu
authors: Dongwan
authors: D
authors: Yoo
authors: Xing
authors: X
authors: Liu
authors: Xiumei
authors: X
authors: Zhang
authors: Jun
authors: J
authors: Li
authors: Wenbo
authors: W
authors: Sun
authors: Xiaoyan
authors: X
authors: Cong
authors: Jianli
authors: J
authors: Shi
authors: Jinbao
authors: J
authors: Wang
mesh_terms: D000818:Animals; D000917:Antibody Formation; D001831:Body Temperature; D049109:Cell Proliferation; D005814:Genes, Viral; D057809:HEK293 Cells; D006801:Humans; D056724:Immunity, Humoral; D007371:Interferon-gamma / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology; D008168:Lung / Q000473:pathology / Q000821:virology; D009500:Neutralization Tests; D010957:Plasmids / Q000235:genetics / Q000378:metabolism; D019318:Porcine Reproductive and Respiratory Syndrome / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D019316:Porcine respiratory and reproductive syndrome virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D013552:Swine / Q000276:immunology / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*; D014766:Viremia / Q000276:immunology / Q000517:prevention & control / Q000821:virology
chemical_list: D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C114789:glycoprotein 5, PRRSV; D015847:Interleukin-4; D007371:Interferon-gamma